

Author index of volume 54

- Aizawa, Y., see Suzuki, K. 54, 173
 Akanuma, Y., see Kawano, M. 54, 41
 Aliyazicioğlu, R., see Vanizor, B. 54, 33
 Araz, M., N. Yilmaz, K. Güngör, V. Okan, Y. Kepekci, A. Sükrü Aynacioglu, Angiotensin-converting enzyme gene polymorphism and microvascular complications in Turkish type 2 diabetic patients 54, 95
 Arokiasamy, T., see Kumaramanickavel, G. 54, 89
 Astorga, R., see Tamás, G. 54, 105
 Awata, T., see Ishii, C. 54, 137

 Baba, S., Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics 54, 191
 Badrinath, S.S., see Kumaramanickavel, G. 54, 89
 Barnett, A.H., see Palin, S.L. 54, 67
 Bril, V., see Olaleye, D. 54, 115
 Buono, P., see Franzese, A. 54, 219

 Çan, G., see Erem, C. 54, 203
 Chao, M.C., see Chen, B.H. 54, 27
 Charalabides, J., see Migdalis, I.N. 54, 129
 Chen, B.H., S.B. Chung, W. Chiang, M.C. Chao, GAD65 antibody prevalence and association with thyroid antibodies, HLA-DR in Chinese children with type 1 diabetes mellitus 54, 27
 Chiang, W., see Chen, B.H. 54, 27
 Chung, S.B., see Chen, B.H. 54, 27
 Clarke, W.L., see Cox, D.J. 54, 17
 Cordopatis, C., see Migdalis, I.N. 54, 129
 Cox, D.J., L.A. Gonder-Frederick, B.P. Kovatchev, W.L. Clarke, Self-treatment of hypoglycemia while driving 54, 17

 Darko, D.A., A. Dornhorst, G. Kennedy, R.C. Mandeno, M. Seed, Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy 54, 157

 Dedov, I., see Tamás, G. 54, 105
 Deger, O., see Erem, C. 54, 203
 Dornhorst, A., see Darko, D.A. 54, 157
 Dzien, A., C. Dzien-Bischinger, F. Hoppichler, M. Lechleitner, Fasting glucose concentrations and cardiovascular disease; are the new diagnostic criteria not strict enough? 54, 213
 Dzien-Bischinger, C., see Dzien, A. 54, 213

 Egusa, G., see Kawamura, T. 54, 49
 Enwemeka, C.S., see Reddy, G.K. 54, 1
 Erem, C., R. Yildiz, H. Kavgaci, C. Karahan, O. Deger, G. Çan, M. Telatar, Prevalence of diabetes, obesity and hypertension in a Turkish population (Trabzon city) 54, 203
 Erem, C., see Vanizor, B. 54, 33

 Franzese, A., R. Iorio, P. Buono, M. Mascolo, E. Mozzillo, G. Valerio, Mauriac syndrome still exists 54, 219
 Fujikawa, R., see Kawamura, T. 54, 49
 Fujishima, M., see Iwase, M. 54, 215
 Funahashi, T., see Nakamura, T. 54, 181

 Gonder-Frederick, L.A., see Cox, D.J. 54, 17
 Gopal, L., see Kumaramanickavel, G. 54, 89
 Gotoh, D., see Iwase, M. 54, 215
 Güngör, K., see Araz, M. 54, 95

 Hamade, S., see Reddy, G.K. 54, 1
 Hamasaki, A., see Taniguchi, T. 54, 143
 Hamasaki, N., see Iwase, M. 54, 215
 Hanabusa, T., see Ogawa, K. 54, 57
 Hanyu, O., see Suzuki, K. 54, 173
 Hashimoto, N., see Sano, R. 54, 79
 Hiratsuka, A., see Kawano, M. 54, 41
 Hirose, T., Y. Miyashita, M. Takagi, S. Sumitani, H. Kouhara, S. Kasayama, Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea 54, 9
 Hoppichler, F., see Dzien, A. 54, 213

- Hotta, K., see Nakamura, T. 54, 181
- Iliopoulou, V., see Migdalis, I.N. 54, 129
- Iorio, R., see Franzese, A. 54, 219
- Ishii, C., K. Inoue, K. Negishi, N. Tane, T. Awata, S. Katayama, Diabetic ketoacidosis in a case of pheochromocytoma 54, 137
- Ishikawa, K., see Nakamura, T. 54, 181
- Iwase, M., D. Gotoh, M. Urata, D. Kang, N. Hamasaki, M. Yoshinari, M. Fujishima, Clinical features of diabetic patients with 0.01–0.1% heteroplasmy A3243G mutation in leukocyte mitochondrial DNA 54, 215
- Jacobsen, J., see Tamás, G. 54, 105
- Joseph, B., see Kumaramanickavel, G. 54, 89
- Kalogeropoulou, K., see Migdalis, I.N. 54, 129
- Kanatsuka, A., see Sano, R. 54, 79
- Kanatsuka, A., see Tokuyama, Y. 54, 209
- Kanazawa, Y., see Kawano, M. 54, 41
- Kang, D., see Iwase, M. 54, 215
- Karahan, C., see Erem, C. 54, 203
- Karahan, S.C., see Vanizor, B. 54, 33
- Kasayama, S., see Hirose, T. 54, 9
- Katayama, S., see Ishii, C. 54, 137
- Katayama, S., see Kawano, M. 54, 41
- Kato, K., see Suzuki, K. 54, 173
- Kavgaci, H., see Erem, C. 54, 203
- Kawakami, M., see Kawano, M. 54, 41
- Kawamoto, T., see Nakamura, T. 54, 181
- Kawamura, T., G. Egusa, R. Fujikawa, M. Okubo, β_3 -adren-
ergic receptor gene variant is associated with upper body
obesity only in obese Japanese-American men but not in
women 54, 49
- Kawano, M., Y. Omori, S. Katayama, M. Kawakami, Y.
Suzuki, K. Takahashi, Y. Takemura, N. Nagata, A. Hirat-
suka, F. Matsuzaki, Y. Kanazawa, Y. Akanuma, A ques-
tionnaire for neurological symptoms in patients with
diabetes — cross-sectional multicenter study in Saitama
Prefecture, Japan 54, 41
- Kennedy, G., see Darko, D.A. 54, 157
- Kepekci, Y., see Araz, M. 54, 95
- Kihara, S., see Nakamura, T. 54, 181
- Kiran, E., see Vanizor, B. 54, 33
- Kishino, B.-i., see Nakamura, T. 54, 181
- Kishi, Y., see Ogawa, K. 54, 57
- Kouhara, H., see Hirose, T. 54, 9
- Kovatchev, B.P., see Cox, D.J. 54, 17
- Kumaramanickavel, G., S. Sriprya, R.N. Vellanki, N.K.
Upadyay, S.S. Badrinath, T. Arokiasamy, B. Sukumar, A.
Vidhya, B. Joseph, T. Sharma, L. Gopal, Tumor necrosis
factor allelic polymorphism with diabetic retinopathy in
India 54, 89
- Kumar, S., see Palin, S.L. 54, 67
- Kuriyama, H., see Nakamura, T. 54, 181
- Lechleitner, M., see Dzien, A. 54, 213
- Lindholm, A., see Tamás, G. 54, 105
- Inoue, K., see Ishii, C. 54, 137
- Lozano, R.A., see Tso, T.K. 54, 165
- Makino, H., see Sano, R. 54, 79
- Makino, H., see Tang, Y. 54, 145
- Mandeno, R.C., see Darko, D.A. 54, 157
- Marre, M., see Tamás, G. 54, 105
- Mascolo, M., see Franzese, A. 54, 219
- Matsuzaki, F., see Kawano, M. 54, 41
- Matsuzawa, Y., see Nakamura, T. 54, 181
- Migdalis, I.N., K. Kalogeropoulou, V. Iliopoulou, P. Tri-
antafilou, J. Charalabides, G. Mortzos, C. Cordopatis,
Plasma levels of endothelin, lipid peroxides and prostacyclin
in diabetic patients with macroangiopathy 54, 129
- Miki, T., see Sano, R. 54, 79
- Mineo, I., see Nakamura, T. 54, 181
- Miyashita, Y., see Hirose, T. 54, 9
- Mortzos, G., see Migdalis, I.N. 54, 129
- Mozzillo, E., see Franzese, A. 54, 219
- Nagata, N., see Kawano, M. 54, 41
- Nakagawa, C., see Nakamura, T. 54, 181
- Nakagawa, O., see Suzuki, K. 54, 173
- Nakamura, T., T. Funahashi, S. Yamashita, M. Nishida, Y.
Nishida, M. Takahashi, K. Hotta, H. Kuriyama, S. Kihara,
N. Ohuchi, T. Nishimura, B.-i. Kishino, K. Ishikawa, T.
Kawamoto, K. Tokunaga, C. Nakagawa, I. Mineo, F.
Watanabe, S. Tarui, Y. Matsuzawa, Thiazolidinedione
derivative improves fat distribution and multiple risk factors
in subjects with visceral fat accumulation—double-blind
placebo-controlled trial 54, 181
- Nakao, T., see Ogawa, K. 54, 57
- Nanjo, K., see Ogawa, K. 54, 57
- Negishi, K., see Ishii, C. 54, 137
- Nishida, M., see Nakamura, T. 54, 181
- Nishida, Y., see Nakamura, T. 54, 181
- Nishimiya, T., see Tang, Y. 54, 145
- Nishi, M., see Ogawa, K. 54, 57
- Nishimura, T., see Nakamura, T. 54, 181
- Nozaki, O., see Tokuyama, Y. 54, 209
- Ochi, M., see Tang, Y. 54, 145
- Ogawa, K., H. Sasaki, Y. Kishi, H. Yamasaki, K. Okamoto,
N. Yamamoto, T. Hanabusa, T. Nakao, M. Nishi, K.
Nanjo, A suspected case of proximal diabetic neuropathy
predominantly presenting with scapulohumeral muscle
weakness and deep aching pain 54, 57
- Ohuchi, N., see Nakamura, T. 54, 181
- Okamoto, K., see Ogawa, K. 54, 57
- Okamoto, M., see Taniguchi, T. 54, 143
- Okamoto, M., see Taniguchi, T. 54, 143
- Okan, V., see Araz, M. 54, 95
- Okubo, M., see Kawamura, T. 54, 49
- Olaleye, D., B.A. Perkins, V. Bril, Evaluation of three screen-
ing tests and a risk assessment model for diagnosing periph-
eral neuropathy in the diabetes clinic 54, 115

- Omori, Y., see Kawano, M. 54, 41
 Onuma, H., see Tang, Y. 54, 145
 Örem, A., see Vanizor, B. 54, 33
 Osawa, H., see Tang, Y. 54, 145
- Palin, S.L., S. Kumar, D.W. Sturdee, A.H. Barnett, HRT in women with diabetes—review of the effects on glucose and lipid metabolism 54, 67
 Perkins, B.A., see Olaleye, D. 54, 115
- Reddy, G.K., L. Stehno-Bittel, S. Hamade, C.S. Enwemeka, The biomechanical integrity of bone in experimental diabetes 54, 1
- Saito, Y., see Sano, R. 54, 79
 Sano, R., T. Miki, Y. Suzuki, F. Shimada, M. Taira, A. Kanatsuka, H. Makino, N. Hashimoto, Y. Saito, Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes 54, 79
 Sasaki, H., see Ogawa, K. 54, 57
 Seed, M., see Darko, D.A. 54, 157
 Seino, Y., see Taniguchi, T. 54, 143
 Sharma, T., see Kumaramanickavel, G. 54, 89
 Shimada, F., see Sano, R. 54, 79
 Snook, J.T., see Tso, T.K. 54, 165
 Sripriya, S., see Kumaramanickavel, G. 54, 89
 Stehno-Bittel, L., see Reddy, G.K. 54, 1
 Sturdee, D.W., see Palin, S.L. 54, 67
 Sugita, A., see Tang, Y. 54, 145
 Sükrü Aynacioglu, A., see Araz, M. 54, 95
 Sukumar, B., see Kumaramanickavel, G. 54, 89
 Sumitani, S., see Hirose, T. 54, 9
 Suzuki, K., K. Kato, O. Hanyu, O. Nakagawa, Y. Aizawa, Left ventricular mass index increases in proportion to the progression of diabetic nephropathy in Type 2 diabetic patients 54, 173
 Suzuki, Y., see Kawano, M. 54, 41
 Suzuki, Y., see Sano, R. 54, 79
- Taira, M., see Sano, R. 54, 79
 Takagi, M., see Hirose, T. 54, 9
 Takahashi, K., see Kawano, M. 54, 41
 Takahashi, M., see Nakamura, T. 54, 181
 Takemura, Y., see Kawano, M. 54, 41
 Tamás, G., M. Marre, R. Astorga, I. Dedov, J. Jacobsen, A. Lindholm, Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study 54, 105
- Tanaka, J., see Taniguchi, T. 54, 143
 Tane, N., see Ishii, C. 54, 137
 Tang, Y., H. Osawa, H. Onuma, T. Nishimiya, M. Ochi, A. Sugita, H. Makino, Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse 54, 145
 Taniguchi, T., M. Okamoto, H. Ueno, J. Tanaka, M. Okamoto, A. Hamasaki, Y. Yamada, Y. Seino, Use of the insulin sensitivity index obtained from oral glucose tolerance test in Japanese subjects 54, 143
 Tarui, S., see Nakamura, T. 54, 181
 Telatar, M., see Erem, C. 54, 203
 Tokunaga, K., see Nakamura, T. 54, 181
 Tokuyama, Y., O. Nozaki, A. Kanatsuka, A patient with subcutaneous-insulin resistance treated by insulin lispro plus heparin 54, 209
 Triantafilou, P., see Migdalis, I.N. 54, 129
 Tso, T.K., J.T. Snook, R.A. Lozano, W.B. Zipf, Risk factors for coronary heart disease in type 1 diabetic children: the influence of apoE phenotype and glycemic regulation 54, 165
- Ueno, H., see Taniguchi, T. 54, 143
 Upadhyay, N.K., see Kumaramanickavel, G. 54, 89
 Urata, M., see Iwase, M. 54, 215
 Uydu, H.A., see Vanizor, B. 54, 33
- Valerio, G., see Franzese, A. 54, 219
 Vanizor, B., A. Örem, S.C. Karahan, E. Kiran, C. Erem, R. Aliyazicioğlu, H.A. Uydu, Decreased nitric oxide end-products and its relationship with high density lipoprotein and oxidative stress in people with type 2 diabetes without complications 54, 33
 Vellanki, R.N., see Kumaramanickavel, G. 54, 89
 Vidhya, A., see Kumaramanickavel, G. 54, 89
- Watanabe, F., see Nakamura, T. 54, 181
- Yamada, Y., see Taniguchi, T. 54, 143
 Yamamoto, N., see Ogawa, K. 54, 57
 Yamasaki, H., see Ogawa, K. 54, 57
 Yamashita, S., see Nakamura, T. 54, 181
 Yildiz, R., see Erem, C. 54, 203
 Yilmaz, N., see Araz, M. 54, 95
 Yoshinari, M., see Iwase, M. 54, 215
- Zipf, W.B., see Tso, T.K. 54, 165



Subject index of volume 54

- Adipocyte**; Phosphodiesterase 3B; Gene expression; Liver; Type 2 diabetes **54**, 145
- β_3 -adrenergic receptor**; Obesity; Insulin resistance **54**, 49
- Albuminuria**; Cardiovascular disease; Diabetic nephropathy; Left ventricular hypertrophy; Type 2 DM **54**, 173
- Allelic polymorphism**; Diabetic retinopathy; Major histocompatibility complex; Tumor necrosis factor; Lymphotoxin **54**, 89
- Angiotensin converting enzyme**; Polymorphism; Type 2 diabetes mellitus; Nephropathy; Retinopathy; Molecular genetics **54**, 95
- apoE phenotype**; Glycemic regulation; Coronary heart disease; Lipoprotein; Type 1 diabetes mellitus **54**, 165
- Bending stiffness**; Bone strength; Bone biomechanics; Bone fragility; Brittle bones; Deformation; Hyperglycemia **54**, 1
- Bone biomechanics**; Bone strength; Bone fragility; Brittle bones; Deformation; Bending stiffness; Hyperglycemia **54**, 1
- Bone fragility**; Bone strength; Bone biomechanics; Brittle bones; Deformation; Bending stiffness; Hyperglycemia **54**, 1
- Bone strength**; Bone biomechanics; Bone fragility; Brittle bones; Deformation; Bending stiffness; Hyperglycemia **54**, 1
- Brittle bones**; Bone strength; Bone biomechanics; Bone fragility; Deformation; Bending stiffness; Hyperglycemia **54**, 1
- Cardiovascular disease**; Diabetic nephropathy; Left ventricular hypertrophy; Albuminuria; Type 2 DM **54**, 173
- Cardiovascular event**; Nifedipine retard; Enalapril; Hypertensive type 2 diabetics; Urinary albumin excretion rate **54**, 191
- Children**; Mauriac syndrome; Type 1 diabetes **54**, 219
- Coronary heart disease**; apoE phenotype; Glycemic regulation; Lipoprotein; Type 1 diabetes mellitus **54**, 165
- Cross-sectional study**; Diabetes mellitus; Neuropathy; Multi-center study; Questionnaire **54**, 41
- 3',5'-Cyclic-nucleotide phosphodiesterase**; Type 2 diabetes mellitus; Single-stranded conformational polymorphism; Restriction fragment length polymorphism; Dinucleotide repeats **54**, 79
- Deformation**; Bone strength; Bone biomechanics; Bone fragility; Brittle bones; Bending stiffness; Hyperglycemia **54**, 1
- Diabetes**; Hormone replacement therapy (HRT); Glucose; Lipids **54**, 67
- Diabetes mellitus**; Neuropathy; Multicenter study; Questionnaire; Cross-sectional study **54**, 41
- Diabetes mellitus**; Screening for neuropathy; Diagnostic test; Risk assessment model **54**, 115
- Diabetes**; Obesity; Prevalence; Turkish population; Trabzon **54**, 203
- Diabetic amyotrophy**; Diabetic proximal neuropathy; Selective serotonin reuptake inhibitor **54**, 57
- Diabetic control**; Type 2 diabetes; Menopause; Hormone replacement therapy; Lipoproteins **54**, 157
- Diabetic ketoacidosis**; Pheochromocytoma; Insulin secretion; Insulin resistance; Obesity **54**, 137
- Diabetic nephropathy**; Cardiovascular disease; Left ventricular hypertrophy; Albuminuria; Type 2 DM **54**, 173

- Diabetic proximal neuropathy;** Diabetic amyotrophy; Selective serotonin reuptake inhibitor **54, 57**
- Diabetic retinopathy;** Allelic polymorphism; Major histocompatibility complex; Tumor necrosis factor; Lymphotoxin **54, 89**
- Diagnostic test;** Screening for neuropathy; Diabetes mellitus; Risk assessment model **54, 115**
- Dinucleotide repeats;** 3',5'-Cyclic-nucleotide phosphodiesterase; Type 2 diabetes mellitus; Single-stranded conformational polymorphism; Restriction fragment length polymorphism **54, 79**
- Driving;** T1DM; Hypoglycemia; Self-treatment; Symptoms **54, 17**
- Enalapril;** Nifedipine retard; Hypertensive type 2 diabetics; Urinary albumin excretion rate; Cardiovascular event **54, 191**
- Endothelin;** Lipid peroxides; Prostacyclin; Macroangiopathy; Type 2 diabetes **54, 129**
- GAD65;** Thyroid autoimmune antibody; Residual beta cell function; HLA-DR **54, 27**
- Gene expression;** Phosphodiesterase 3B; Adipocyte; Liver; Type 2 diabetes **54, 145**
- Glucose;** Hormone replacement therapy (HRT); Diabetes; Lipids **54, 67**
- α -Glucosidase inhibitor;** Voglibose; Sulfonylurea; Homeostasis model assessment (HOMA) **54, 9**
- Glycaemic control;** Insulin aspart; Human insulin; Type 1 diabetes **54, 105**
- Glycemic regulation;** apoE phenotype; Coronary heart disease; Lipoprotein; Type 1 diabetes mellitus **54, 165**
- Heparin;** Subcutaneous-insulin resistance; Insulin lispro **54, 209**
- High density lipoprotein;** Oxidative stress; Nitric oxide end-products; Type 2 diabetes mellitus **54, 33**
- HLA-DR;** GAD65; Thyroid autoimmune antibody; Residual beta cell function **54, 27**
- Homeostasis model assessment (HOMA);** α -Glucosidase inhibitor; Voglibose; Sulfonylurea **54, 9**
- Hormone replacement therapy (HRT);** Diabetes; Glucose; Lipids **54, 67**
- Hormone replacement therapy;** Type 2 diabetes; Menopause; Lipoproteins; Diabetic control **54, 157**
- Human insulin;** Insulin aspart; Glycaemic control; Type 1 diabetes **54, 105**
- Hyperglycemia;** Bone strength; Bone biomechanics; Bone fragility; Brittle bones; Deformation; Bending stiffness **54, 1**
- Hypertensive type 2 diabetics;** Nifedipine retard; Enalapril; Urinary albumin excretion rate; Cardiovascular event **54, 191**
- Hypoglycemia;** Driving; T1DM; Self-treatment; Symptoms **54, 17**
- Insulin aspart;** Human insulin; Glycaemic control; Type 1 diabetes **54, 105**
- Insulin lispro;** Subcutaneous-insulin resistance; Heparin **54, 209**
- Insulin resistance;** β_3 -adrenergic receptor; Obesity **54, 49**
- Insulin resistance;** Pheochromocytoma; Diabetic ketoacidosis; Insulin secretion; Obesity **54, 137**
- Insulin resistance;** Thiazolidinedione derivative; Troglitazone; Visceral fat; Multiple risk factor **54, 181**
- Insulin secretion;** Pheochromocytoma; Diabetic ketoacidosis; Insulin resistance; Obesity **54, 137**
- Left ventricular hypertrophy;** Cardiovascular disease; Diabetic nephropathy; Albuminuria; Type 2 DM **54, 173**
- Lipid peroxides;** Endothelin; Prostacyclin; Macroangiopathy; Type 2 diabetes **54, 129**
- Lipids;** Hormone replacement therapy (HRT); Diabetes; Glucose **54, 67**
- Lipoprotein;** apoE phenotype; Glycemic regulation; Coronary heart disease; Type 1 diabetes mellitus **54, 165**
- Lipoproteins;** Type 2 diabetes; Menopause; Hormone replacement therapy; Diabetic control **54, 157**
- Liver;** Phosphodiesterase 3B; Gene expression; Adipocyte; Type 2 diabetes **54, 145**
- Lymphotoxin;** Allelic polymorphism; Diabetic retinopathy; Major histocompatibility complex; Tumor necrosis factor **54, 89**
- Macroangiopathy;** Endothelin; Lipid peroxides; Prostacyclin; Type 2 diabetes **54, 129**
- Major histocompatibility complex;** Allelic polymorphism; Diabetic retinopathy; Tumor necrosis factor; Lymphotoxin **54, 89**
- Mauriac syndrome;** Type 1 diabetes; Children **54, 219**

- Menopause**; Type 2 diabetes; Hormone replacement therapy; Lipoproteins; Diabetic control **54**, 157
- Molecular genetics**; Angiotensin converting enzyme; Polymorphism; Type 2 diabetes mellitus; Nephropathy; Retinopathy **54**, 95
- Multicenter study**; Diabetes mellitus; Neuropathy; Questionnaire; Cross-sectional study **54**, 41
- Multiple risk factor**; Thiazolidinedione derivative; Troglitazone; Insulin resistance; Visceral fat **54**, 181
- Nephropathy**; Angiotensin converting enzyme; Polymorphism; Type 2 diabetes mellitus; Retinopathy; Molecular genetics **54**, 95
- Neuropathy**; Diabetes mellitus; Multicenter study; Questionnaire; Cross-sectional study **54**, 41
- Nifedipine retard**; Enalapril; Hypertensive type 2 diabetics; Urinary albumin excretion rate; Cardiovascular event **54**, 191
- Nitric oxide end-products**; High density lipoprotein; Oxidative stress; Type 2 diabetes mellitus **54**, 33
- Obesity**; β_3 -adrenergic receptor; Insulin resistance **54**, 49
- Obesity**; Diabetes; Prevalence; Turkish population; Trabzon **54**, 203
- Obesity**; Pheochromocytoma; Diabetic ketoacidosis; Insulin secretion; Insulin resistance **54**, 137
- Oxidative stress**; High density lipoprotein; Nitric oxide end-products; Type 2 diabetes mellitus **54**, 33
- Pheochromocytoma**; Diabetic ketoacidosis; Insulin secretion; Insulin resistance; Obesity **54**, 137
- Phosphodiesterase 3B**; Gene expression; Adipocyte; Liver; Type 2 diabetes **54**, 145
- Polymorphism**; Angiotensin converting enzyme; Type 2 diabetes mellitus; Nephropathy; Retinopathy; Molecular genetics **54**, 95
- Prevalence**; Diabetes; Obesity; Turkish population; Trabzon **54**, 203
- Prostacyclin**; Endothelin; Lipid peroxides; Macroangiopathy; Type 2 diabetes **54**, 129
- Questionnaire**; Diabetes mellitus; Neuropathy; Multicenter study; Cross-sectional study **54**, 41
- Residual beta cell function**; GAD65; Thyroid autoimmune antibody; HLA-DR **54**, 27
- Restriction fragment length polymorphism**; 3',5'-Cyclic-nucleotide phosphodiesterase; Type 2 diabetes mellitus; Single-stranded conformational polymorphism; Dinucleotide repeats **54**, 79
- Retinopathy**; Angiotensin converting enzyme; Polymorphism; Type 2 diabetes mellitus; Nephropathy; Molecular genetics **54**, 95
- Risk assessment model**; Screening for neuropathy; Diagnostic test; Diabetes mellitus **54**, 115
- Screening for neuropathy**; Diagnostic test; Diabetes mellitus; Risk assessment model **54**, 115
- Selective serotonin reuptake inhibitor**; Diabetic proximal neuropathy; Diabetic amyotrophy **54**, 57
- Self-treatment**; Driving; T1DM; Hypoglycemia; Symptoms **54**, 17
- Single-stranded conformational polymorphism**; 3',5'-Cyclic-nucleotide phosphodiesterase; Type 2 diabetes mellitus; Restriction fragment length polymorphism; Dinucleotide repeats **54**, 79
- Subcutaneous-insulin resistance**; Insulin lispro; Heparin **54**, 209
- Sulfonylurea**; α -Glucosidase inhibitor; Voglibose; Homeostasis model assessment (HOMA) **54**, 9
- Symptoms**; Driving; T1DM; Hypoglycemia; Self-treatment **54**, 17
- T1DM**; Driving; Hypoglycemia; Self-treatment; Symptoms **54**, 17
- Thiazolidinedione derivative**; Troglitazone; Insulin resistance; Visceral fat; Multiple risk factor **54**, 181
- Thyroid autoimmune antibody**; GAD65; Residual beta cell function; HLA-DR **54**, 27
- Trabzon**; Diabetes; Obesity; Prevalence; Turkish population **54**, 203
- Troglitazone**; Thiazolidinedione derivative; Insulin resistance; Visceral fat; Multiple risk factor **54**, 181
- Tumor necrosis factor**; Allelic polymorphism; Diabetic retinopathy; Major histocompatibility complex; Lymphotoxin **54**, 89
- Turkish population**; Diabetes; Obesity; Prevalence; Trabzon **54**, 203
- Type 2 diabetes**; Endothelin; Lipid peroxides; Prostacyclin; Macroangiopathy **54**, 129
- Type 1 diabetes**; Insulin aspart; Human insulin; Glycaemic control **54**, 105

Type 1 diabetes; Mauriac syndrome; Children **54**, 219

Type 2 diabetes mellitus; Angiotensin converting enzyme; Polymorphism; Nephropathy; Retinopathy; Molecular genetics **54**, 95

Type 1 diabetes mellitus; apoE phenotype; Glycemic regulation; Coronary heart disease; Lipoprotein **54**, 165

Type 2 diabetes mellitus; 3',5'-Cyclic-nucleotide phosphodiesterase; Single-stranded conformational polymorphism; Restriction fragment length polymorphism; Dinucleotide repeats **54**, 79

Type 2 diabetes mellitus; High density lipoprotein; Oxidative stress; Nitric oxide end-products **54**, 33

Type 2 diabetes; Menopause; Hormone replacement therapy; Lipoproteins; Diabetic control **54**, 157

Type 2 diabetes; Phosphodiesterase 3B; Gene expression; Adipocyte; Liver **54**, 145

Type 2 DM; Cardiovascular disease; Diabetic nephropathy; Left ventricular hypertrophy; Albuminuria **54**, 173

Urinary albumin excretion rate; Nifedipine retard; Enalapril; Hypertensive type 2 diabetics; Cardiovascular event **54**, 191

Visceral fat; Thiazolidinedione derivative; Troglitazone; Insulin resistance; Multiple risk factor **54**, 181

Voglibose; α -Glucosidase inhibitor; Sulfonylurea; Homeostasis model assessment (HOMA) **54**, 9

